Skip to content
Baret News – Lifestyle
Author:
Harbour Biomed
Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
September 6, 2026
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
August 27, 2026
Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
August 27, 2026
Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
August 18, 2026
Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies
August 6, 2026
Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium
July 27, 2026
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
July 23, 2026
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma
July 15, 2026
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
June 28, 2026
Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven Complex Biologics R&D
June 15, 2026
1
2
3
Next Page
→